BioCentury | Apr 3, 2021
Deals
April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid
...to repurchase up to $1.2 billion in outstanding shares over the next 12-18 months.Royalty buys GSK's...
...a royalty interest in Cabometyx cabozantinib, which is also marketed as Cometriq, from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...receive GSK's share of net ex-U.S. sales through the full term of the royalties and GSK's...
...a royalty interest in Cabometyx cabozantinib, which is also marketed as Cometriq, from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...receive GSK's share of net ex-U.S. sales through the full term of the royalties and GSK's...